Orchestra BioMed Inc.

2.79
0.21 (8.14%)
At close: Apr 25, 2025, 3:59 PM
2.61
-6.36%
Pre-market: Apr 28, 2025, 06:51 AM EDT

Company Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.

The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.

Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.

The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.

Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Orchestra BioMed Inc.
Orchestra BioMed  Inc. logo
Country United States
IPO Date Aug 4, 2020
Industry Biotechnology
Sector Healthcare
Employees 70
CEO David P. Hochman

Contact Details

Address:
150 Union Square Drive
New Hope, Pennsylvania
United States
Website https://orchestrabiomed.com

Stock Details

Ticker Symbol OBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001814114
CUSIP Number 68572M106
ISIN Number US68572M1062
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
David P. Hochman Founder, Chairman of the Board of Directors & Chief Executive Officer
Andrew Lawrence Taylor M.B.A. Chief Financial Officer
Darren R. Sherman Founder, President, Chief Operating Officer & Director
Dr. Yuval Hay Mika D.Sc, Ph.D. GM & Chief Technology Officer of Bioelectronic Therapies
Bob Laughner Senior Vice President of Regulatory & Quality
Dr. Avraham Matityahu Fischer M.D. Senior Vice President of Medical Affairs & Innovation
Dr. Hans-Peter Stoll M.D., Ph.D. Chief Clinical Officer
Juan Lorenzo Senior Vice President of Product Development
Mark Pomeranz GM & Executive Vice President of Interventional Therapies
William Reed Little Executive Vice President of Corporate Development & Strategy

Latest SEC Filings

Date Type Title
Apr 04, 2025 4 Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 4 Filing
Mar 31, 2025 10-K Annual Report
Mar 28, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 03, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 19, 2025 S-8 Filing